Mifamurtide sodium (MTP-PE sodium) 是穆拉基二肽 (MDP) 的类似物,一种非特异性免疫调节剂,通过刺激激活巨噬细胞和单核细胞的免疫应答而发挥作用。Mifamurtide sodium 是一种孤儿药,是 NOD2 的特异性配体,用作胰岛素增敏剂。Mifamurtide sodium 具有用于骨肉瘤研究的潜力。
生物活性 | Mifamurtide sodium (MTP-PE sodium), an analog of the muramyl dipeptide (MDP), is a nonspecific immunomodulator by stimulating the immune response activating macrophages and monocytes. Mifamurtide sodium, an orphan drug, is a specific ligand ofNOD2used as aninsulinsensitizer. Mifamurtide sodium has the potential for osteosarcoma research[1][2][3]. |
IC50& Target | |
体外研究 (In Vitro) | Mifamurtide sodium (MTP-PE sodium; 100 μM) induces a reduction of MG63 cells number when co-cultured with macrophages[3]. Mifamurtide sodium (100 μM) increases both the M1 polarization marker iNOS and the M2 polarization marker CD206 mRNAs; both pro-inflammatory (IL-1β, IL-6) and anti-inflammatory (IL-4, IL-10) cytokines. Mifamurtide sodium increases the iron transporter DMT1 protein[3]. L-mifamurtide sodium (5, 5000 nM; for 48 hours) alone has no direct effect on the proliferation rate of the two osteosarcoma cell lines MOS-J and KHOS in vitro or in vivo[1]. Mifamurtide sodium acts as a nonspecific immunomodulator by activating macrophages and monocytes related to the upregulation of tumoricidal activity and secretion of pro-inflammatory cytokines including tumor necrosis factor (TNF)-a, interleukin (IL)-1, IL-6, IL-8, IL-12, nitric oxide (NO), prostaglandin E2 (PGE2) and PGD2[3].
|
体内研究 (In Vivo) | Mifamurtide sodium (MTP-PE sodium; 1 mg/kg; i.v.; twice per week for 4 weeks) causes a trend of diminished spontaneous lung metastasis dissemination[1]. Mifamurtide sodium (50 μg/mouse) improves glucose tolerance during endotoxemia in mice. Mifamurtide sodium (equivalent to 20 μg MDP; 4 times per week for 5 weeks) improves glucose tolerance in HFD-fed mice without altering body mass[2].
Animal Model: | C57BL/6, BALB/c mice with KHOS osteosarcoma cells[1] | Dosage: | 1 mg/kg | Administration: | IV; twice per week for 4 weeks | Result: | Caused a trend of diminished spontaneous lung metastasis dissemination in xenogeneic (KHOS) and syngeneic (MOS-J) models. |
|
Clinical Trial | |
分子量 | |
性状 | |
Formula | |
CAS 号 | |
中文名称 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
溶解性数据 | In Vitro: DMSO : 50 mg/mL(39.70 mM;Need ultrasonic) 配制储备液 1 mM | 0.7940 mL | 3.9699 mL | 7.9398 mL | 5 mM | 0.1588 mL | 0.7940 mL | 1.5880 mL | 10 mM | 0.0794 mL | 0.3970 mL | 0.7940 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 5 mg/mL (3.97 mM); Clear solution
此方案可获得 ≥ 5 mg/mL (3.97 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: 5 mg/mL (3.97 mM); Suspended solution; Need ultrasonic
此方案可获得 5 mg/mL (3.97 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。 以 1 mL 工作液为例,取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 3. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 5 mg/mL (3.97 mM); Clear solution
此方案可获得 ≥ 5 mg/mL (3.97 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|